Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-02-17
2011-12-06
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S124000, C536S123100
Reexamination Certificate
active
08071569
ABSTRACT:
The present invention relates to a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 4,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. The present invention also relates to methods of inhibiting angiogenesis and treating an angiogenesis-mediated disorder in a subject by administering a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 30,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. Another aspect of the present invention relates to compositions including the heparin fractions of the present invention.
REFERENCES:
patent: 4727063 (1988-02-01), Naggi et al.
patent: 4973580 (1990-11-01), Mascellani et al.
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5112946 (1992-05-01), Maione
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5202352 (1993-04-01), Okada et al.
patent: 5280016 (1994-01-01), Conrad et al.
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5908837 (1999-06-01), Cohen et al.
patent: 6075013 (2000-06-01), Weitz et al.
patent: 6461665 (2002-10-01), Scholander
Office Action (Mail Date Jun. 27, 2005) for U.S. Appl. No. 10/667,216,—filed Sep. 19, 2003, First Named Inventor: Shaker A. Mousa; Confirmation No. 7027.
Final Office Action (Mail Date Mar. 8, 2006) for U.S. Appl. No. 10/667,216,—filed Sep. 19, 2003, First Named Inventor: Shaker A. Mousa; Confirmation No. 7027.
Office Action (Mail Date Oct. 1, 2007) for U.S. Appl. No. 10/667,216,—filed Sep. 19, 2003, First Named Inventor: Shaker A. Mousa; Confirmation No. 7027.
Final Office Action (Mail Date Apr. 9, 2008) for U.S. Appl. No. 10/667,216,—filed Sep. 19, 2003, First Named Inventor: Shaker A. Mousa; Confirmation No. 7027.
Office Action (Mail Date Oct. 27, 2008) for U.S. Appl. No. 10/667,216,—filed Sep. 19, 2003, First Named Inventor: Shaker A. Mousa; Confirmation No. 7027.
Decision on Appeal (Mail Date Sep. 29, 2010) for U.S. Appl. No. 10/667,216,—filed Sep. 19, 2003, First Named Inventor: Shaker A. Mousa; Confirmation No. 7027.
Decision on Reconsideration—Denied (Mail Date Dec. 21, 2010) for U.S. Appl. No. 10/667,216,—filed Sep. 19, 2003, First Named Inventor: Shaker A. Mousa; Confirmation No. 7027.
Definition of inhibit, Dictionary.com, http://dictionary.reference.com, accessed online on Apr. 2, 2008. Final Office Action (Mail Date Apr. 9, 2008) for U.S. Appl. No. 10/667,216.
Kerbel et al. Cancer and Metastasis Reviews, 20, 2001, p. 79-86.* Final Office Action (Mail Date Apr. 9, 2008) for U.S. Appl. No. 10/667,216.
Definition of Activated Partial Thromboplastin Time, Massacheusetts General Hospital Pathology Service, http://www.massgeneral.org, accessed on Oct. 20, 2008.* Office Action (Mail Date Oct. 27, 2008) for U.S. Appl. No. 10/667,216.
Definition of Heparin Antifactor Xa Assay, Massachusetts General Hospital Pathology Service, http://www.massgeneral.org, accessed online on Oct. 20, 2008.* Office Action (Mail Date Oct. 27, 2008) for U.S. Appl. No. 10/667,216.
Braswell, E., “Heparin: Molecular Weight and Degradation Studies,” Biochim. Biophys. Acta 185: 103-116 (1968).
Kosakai et al., “Isolation and Characterization of Sulfated Disaccharides from the Deamination Products of Porcine Heparin (α-Heparin) and Whale Heparin (ω-Heparin), and a Comparison of the Deamination Products,” J. Biochem. 83: 1567-1575 (1978).
Fransson et al., “Relationship Between Anticoagulant Activity of Heparin and Susceptibility to Periodate Oxidation,” FEBS Letters 97: 119-123 (1979).
Fujita et al. “Improvement of Treadmill Capacity and Collateral Circulation as a Result of Exercise with Heparin Pretreatment in Patients with Effort Angina,” Circulation 77: 1022-1029 (1988).
Rastinejad et al., “Regulation of the Activity of a New Inhibitor of Angiogenesis by a Cancer Suppressor Gene,” Cell 56: 345-355 (1989).
Moses et al., “Identification of an Inhibitor of Neovascularization from Cartilage,” Science 248: 1408-1410 (1990).
Blood et al., “Tumor Interactions with the Vasculature: Angiogenesis and Tumor Metastasis,” Biochim. Biophys. Acta 1032: 89-118 (1990).
Oikawa et al., “Angiogenic Factor of a Rat Mammary Tumor Cell Line (RMT-1) (I). Secretion of Two Distinct Angiogenic Factors into Serum-Free Conditioned Medium by RMT-1 Cells,” Cancer Letters 59: 57-66 (1991).
Buckley et al., “Enoxaparin: A Review of its Pharmacology and Clinical Applications in the Prevention and Treatment of Thromboembolic Disorders,” Drugs 44: 465-497 (1992).
Clapp et al., “The 16-Kilodalton N-Terminal Fragment of Human Prolactin Is a Potent Inhibitor of Angiogenesis,” Endocrinology 133: 1292-1299 (1993).
O'Reilly et al., “Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases,” Cell 79: 315-328 (1994).
Chen et al., “A Strategy to Discover Circulating Angiogenesis Inhibitors Generated by Human Tumors,” Cancer Research 55: 4230-4233 (1995).
Schnaper et al., “Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways,” Journal of Cellular Physiology 165: 107-118 (1995).
Larnkjaer et al., “Isolation and Characterization of Hexasaccharides Derived from Heparin. Analysis of HPLC and Elucidation of Structure by 1H NMR,” Carbohydrate Research 266: 37-52 (1995).
Strieter et al. “Interferon γ-Inducible Protein 10 (IP-10), a Member of the C-X-C Chemokine Family, is an Inhibitor of Angiogenesis,” Biochemical and Biophysical Research Communications 210: 51-57 (1995).
Angiolillo et al., “Human Interferon-inducible Protein 10 is a Potent Inhibitor of Angiogenesis in Vivo,” J. Experimental Medicine 182: 155-162 (1995).
Parangi et al., “Antiangiogenic Therapy of Transgenic Mice Impairs de novo Tumor Growth,” Proc. Natl. Acad. Sci. USA 93: 2002-2007 (1996).
Risau, “Mechanisms of Angiogenesis,” Nature 386: 671-674 (1997).
Mulloy et al., “Molecular Weight Measurements of Low Molecular Weight Heparins by Gel Permeation Chromatography,” Thrombosis and Haemostasis 4: 668-674 (1997).
Dickinson et al., “Enoxaparin Increases the Incidence of Postoperative Intracranial Hemorrhage when Initiated Preoperatively for Deep Venous Thrombosis Prophylaxis in Patients with Brain Tumors,” Neurosurgery 43: 1074-1081 (1998).
Linhardt et al., “Production and Chemical Processing of Low Molecular Weight Heparins,” Seminars in Thrombosis and Haemostasis 25: 5-16 (1999).
Kosir et al., “Degradation of Basement Membrane by Prostate Tumor Heparanase,” Journal of Surgical Research 81: 42-47 (1999).
Kakkar et al., “Antithrombotic Therapy in Cancer,” BMJ 318: 1571-1572 (1999).
Hettiarachchi et al., “Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread,” Thrombosis and Haemostasis 82: 947-952 (1999).
Mousa et al., “Comparative In Vitro Efficacy of Different Platelet Glycoprotein IIb/IIIa Antagonists on Platelet-Mediated Clot Strength Induced by Tissue Factor With Use of Thromboelastography,” Arterioscler. Thromb. Vasc. Biol. 20: 1162-1167 (2000).
Arkel, “Thrombosis and Cancer,” Seminars in Oncology 27: 362-374 (2000).
Zacharski et al., “Low-Molecular-Weight Heparin and Cancer,” Seminars in Thrombosis and Hemostasis 26: 69-77 (2000).
Eriksson et al., “Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism After Hip-Fracture Surgery,” N. Engl. J. Med. 345: 1298-1304 (2001).
Smorenburg et al., “The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental Studies,” Pharmacological Reviews 53: 93-105 (2001).
Mousa et al., “Comparison of the Effect of Different Platelet GPIIb/
Jiang Shaojia Anna
Lau Jonathan S
Schmeiser Olsen & Watts LLP
LandOfFree
Oxidized heparin fractions and their use in inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxidized heparin fractions and their use in inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxidized heparin fractions and their use in inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4316341